^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Truxima (rituximab-abbs)

    i
    Other names: CT-P10
    Company:
    Celltrion, Indukern, Mundipharma, Nippon Kayaku, Teva
    Drug class:
    CD20 inhibitor
    Related drugs:
    3years
    To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma (clinicaltrials.gov)
    P3, N=258, Completed, Celltrion | Active, not recruiting --> Completed | N=174 --> 258
    Trial completion • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs)
    over3years
    [VIRTUAL] Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma (ASH 2020)
    Between Nov 9, 2015 and Jan 4, 2018, 258 patients were randomised (130 CT-P10; 128 rituximab). (Figure A. OS; Figure B. PFS and Figure C. TTP) Over the study period, 114 (88%) and 104 (81%) patients in the CT-P10 and rituximab groups, respectively, experienced at least one treatment-emergent adverse event (TEAE) and 14 (11%) patients in each group experienced TE-serious adverse events (TESAEs). There were no unexpected safety findings observed during the second year of the maintenance period after single transition from rituximab to CT-P10.
    Clinical
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Truxima (rituximab-abbs)